The Phase 3, double-blind, placebo-controlled CLEAR (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) study randomized 345 patients with hypercholesterolemia and a history of intolerance to at least two statins (including one at the lowest available dose) at a 2:1 ratio to receive 180 mg of bempedoic acid or a placebo once daily for 24 weeks. This evidence concerns the gene ACLY and familial hypercholesterolemia.